Led by cancer standout Darzalex, Johnson & Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.
